MedTrace Logo

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

NCT06689241 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2025-04-22

No results posted yet for this study

Summary

Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial

Conditions

  • Morbid Obesity
  • Bariatric Surgery Candidate

Interventions

DRUG

Enoxaparin

40mg

DRUG

rivaroxaban

10mg

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • sarah m elgamal, MD · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-12-01
Completion
2026-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689241 on ClinicalTrials.gov